Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Coloplast Meet the Management London 2017
15 slides from Coloplast A/s Class B's conference presentation, 2017
Slide 1: Group Strategy Update
Group Strategy Update Coloplast Meet the Management London 2017 Lars Rasmussen, President & CEO
Slide 2: Last year we launched LEAD20 and significant progress has already been made
INTRODUCTION Last year we launched our new strategy LEAD20 and significant progress has already been made… Superior products and innovation Unique user-focused market Unparalleled efficiency approach Innovation Excellence Direct ramp up at volume sites + 500,000 enrolments SenSura® Mio SenSura® Mio
Slide 3: We continue to gain market share across our business areas
INTRODUCTION … and we continue to gain market share across our business areas Market share development Percentage point increase from 15/16 to YTD 16/17 +1% +1% +0% +1% Market share 35-40% ~40% 7-9% 10-15% Market position #1 #1 #5 #4 Source: Coloplast • . Page 3
Slide 4: Today we will focus on two of the four themes
INTRODUCTION Today we will focus on two of the four themes 2 1 Understanding users’ lives in full Creating Fighting life-changing for products and better care services Supporting beyond expectations Page 4
Slide 5: Increasing our proximity to consumers, clinicians and payors
1 UNIQUE USER FOCUSED MARKET APPROACH We have a continuous focus on increasing our proximity to consumers, clinicians and payors … In the past we have focused on products with educational In key markets, for example the US we are expanding our services service offering towards hospital and users + P
Slide 6: An attractive value proposition for consumers, clinicians, payors and Coloplast
1 UNIQUE USER FOCUSED MARKET APPROACH … which generates an attractive value proposition for consumers, clinicians, payors and Coloplast It’s an opportunity to secure patients access to 1 our superior products… … and deliver better service to 2 payors, clinicians and users through data and insights…
Slide 7: Clinical Performance Program to tackle the biggest issues users face
2 SUPERIOR PRODUCTS AND INNOVATION We have now initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? 45 %* of users describe UTIs are their 93 % worry about lea
Slide 8: SenSura Mio Convex has demonstrated the impact of improved clinical performance
2 SUPERIOR PRODUCTS AND INNOVATION SenSura® Mio Convex has demonstrated the impact of improved clinical performance Revenue growth, MAT 2013/14 Index 100 reduction in leakage increase in baseplates Bags & Plates total 12% area UNDER the 23% WITHOUT any type of Bags & Plates total baseplate [1]** lea
Slide 9: During 2018 we will launch our next generation coating technology
2 SUPERIOR PRODUCTS AND INNOVATION During 2018 we will launch our next generation coating technology Reduction of bacteria >50% adhering to the catheter [2]** • Today there are no bacteria repellent intermittent catheters on the market • The safety and comfort from current SpeediCath, but with the a
Slide 10: Payors control product accessibility and price through reimbursement
2 SUPERIOR PRODUCTS AND INNOVATION Payors are an essential stakeholder to address, as they control product accessibility & price through reimbursement > 90% of Coloplast revenue is not funded directly by … Addressing payers calls for a separate value consumers but by 3rd party Payors… proposition as
Slide 11: Majority of revenue comes from reimbursement markets linking premiums to outcome
2 SUPERIOR PRODUCTS AND INNOVATION The majority of CP revenue comes from reimbursement markets that link premiums/categories to outcome Reimbursement/ Reimbursement/ Lump sums Procurement/ Out of pocket Brand specific Fixed categories Tenders Feature / price based Performance / value based • . Page
Slide 12: Recently achieved premiums linked to outcome
2 SUPERIOR PRODUCTS AND INNOVATION We have recently achieved premiums linked to outcome and this is the aim of our clinical performance programme Examples of outcome based premiums Shift in pricing/reimbursement focus SpeediCath Compact premium Increased Quality of Life (QoL) Speed to market Line ex
Slide 13: New clinical ambition requires increased investments and organizational strengthening
2 SUPERIOR PRODUCTS AND INNOVATION Delivering on the new clinical ambition will require increased investments and continued strengthening of our organization Organizational implications of new clinical ambition Products - Additional focus on project risk handling Evidence - Clinical evidence will re
Slide 14: Investing in business cases to deliver 7-9% revenue growth ambition
We continue to invest in attractive business cases to deliver our 7-9% revenue growth ambition Key strategic initiatives Commercial investments in pockets of growth Innovation US UK Wound care Pacific Consumer New investments in Emerging Markets • . Page 14
Slide 15: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast A/S - Ostomy Care / C
Coloplast — Coloplast Meet the Management London 2017 on 6ix